Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer

Clinical Cancer Research

Volumn 10, Issue 17, 2004, Pages 5754-5761

  Dang, Chau T ^a   D'Andrea, Gabriella M ^a   Moynahan, Mary E ^a   Dickler, Maura N ^a   Seidman, Andrew D ^a   Fornier, Monica ^a   Robson, Mark E ^a   Theodoulou, Maria ^a   Lake, Diana ^a   Currie, Violante E ^a   Hurria, Arti ^a   Panageas, Katherine S ^a   Norton, Larry ^a   Hudis, Clifford A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TAXANE DERIVATIVE;

ABSCESS; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DYSPEPSIA; DYSPNEA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRANULOCYTOPENIA; HEADACHE; HERPES ZOSTER; HOSPITAL ADMISSION; HUMAN; LACRIMAL GLAND DISEASE; MIGRAINE; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; OTITIS; PAROTID GLAND DISEASE; PERICARDIAL EFFUSION; PERICARDIOTOMY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME; UPPER RESPIRATORY TRACT INFECTION; VISUAL IMPAIRMENT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPH NODES; MIDDLE AGED; PACLITAXEL; PILOT PROJECTS; RISK FACTORS; SURVIVAL RATE; TAXOIDS;

EID: 4444339090     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0634     Document Type: Article

References (34)

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998;352:930-42.
2. Fisher B, Bauer M, Wickerman DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983;52:1551-7.
3. Saez RA, McGuire WL, Clark GM. Prognostic factors in breast cancer. Sem Surg Oncol 1989;5:102-10.
4. th Edition. Williams and Wilkins, Baltimore: 2003. pp. 645-668.
5. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163-9.
6. Bonadonna G, Zambette M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. J Am Med Assoc 1995;273:542-7.
7. Hudis C, Seidman A, Baselga J, et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for respectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 1999;17:93-100.
8. Hudis C, Fornier M, Riccio L, et al. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: a phase II study. J Clin Oncol 1999;17:1118-26.
9. Fornier MN, Seidman AD, Theodoulou M, et al. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma Clin Cancer Res 2001;7:3934-41.
10. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003;21:1431-9.
11. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-61.
12. Green MC, Buzdar AU, Smith T, et al. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete response (pCR) rates when compare to every 3-week (Q 3 wk) P therapy (tx) followed by FAC - final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002;21:135a.
13. Jones S, Erban J, Overmoyer B, et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Breast Cancer Res and Treat 2003;71:10a.
14. The French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-Year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19:602-11.
15. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986;4:1162-70.
16. Von Hoff DD, Clark GM, Weiss GR, et al. Use of in vitro dose-response effect to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 1986;4:1827-34.
17. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205-11.
18. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15:1858-69.
19. Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999;17:3374-88.
20. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from the adding sequential paclitaxel (T) but not from the escalation of doxorubicin A in the adjuvant chemotherapy of patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
21. Mamounas EP, Bryant J, Lembersky BC, et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP-B 28. Proc Am Soc Clin Oncol 2003;22:12a.
22. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-9.
23. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-8.
24. Hainsworth JD, Burris HA, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Res. Network phase II trial. J Clin Oncol 2001;19:3500-5.
25. Chevallier B, Fumoleau P, Kerbat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II study of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995;13:314-22.
26. Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer J Clin Oncol 1996;14:58-65.
27. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute if Canada - Clinical Trials Group. J Clin Oncol 1996;14:422-8.
28. Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-85.
29. Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997;15:3149-55.
30. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer The 303 Study Group. J Clin Oncol 1999;17:2341-54.
31. Nabholz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413-24.
32. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:2651-8.
33. Therasse P, Mauriac L, Welnicka-Jadkiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin ad cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2002;21:843-50.
34. Untch M, Thomssen C, Steffen K, et al. Five year results of a randomized multicenter dose intense (DI-EC) study with epirubicin (E) and cyclophosphamide (C) in high risk breast cancer patients - a treatment of short duration with comparable efficacy to conventional chemotherapy. Breast Cancer Res and Treat 2002;70:641a.